One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Congestive Heart Failure (CHF) Treatment Devices Market

[ 英語タイトル ] Congestive Heart Failure (CHF) Treatment Devices Market - Growth, Trends, and Forecasts (2020 - 2025)

Product Code : MDHC0089288
Survey : Mordor Intelligence
Publish On : November, 2020
Number of Pages : 111
Category : Healthcare and Pharmaceuticals
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
 - Abbott Laboratories
- Berlin Heart
- Biotronik SE & Co. KG
- Boston Scientific Corporation
- Jarvik Heart Inc.
- Medtronic Plc
- ReliantHeart Inc.
- Siemens Healthcare
- Teleflex Incorporated

[Report Description]

The global congestive heart failure treatment devices market is anticipated to register a CAGR of about 8.1% during the forecast period. An increasing patient pool of cardiovascular diseases (CVDs) is one of the prime factors augmenting the growth of the CHF treatment devices market. Sedentary lifestyles, junk food consumption, and mental stress are other key factors associated with the development of CVDs. As per the World Health Organization, in 2019, cardiovascular disease is the leading cause of death globally, taking an estimated 17.9 million lives each year. As a result, the huge target population is positively impacting the growth of the congestive heart failure treatment devices market.

The increasing geriatric population is also leading to upsurge in the cases of CVDs worldwide. This demographic is prone to chronic diseases including CVDs and is characterized by low immunity levels, and thereby serves as a high impact rendering driver for the growth of these products over the forecast period. As a result, the latest treatments available in cardiac care are expected to increase the life span of the elderly population subset.

Supportive government legislation and initiatives in the emerging economies and improving healthcare infrastructure to spread awareness about CVDs occurring in population is working as a growth stimulant to overall market. The developing countries are focusing more on increasing reach of heart diseases awareness programs, which in turn is expected to trigger the adoption of these devices. In addition, technological advancement such as integration of digital platforms with CHF treatment devices is working in favor of the overall market. However, the high cost of CHF treatment devices may hamper the growth of the market.

Key Market Trends

The Implantable Cardioverter Defibrillators form Product Segment is expected to witness the fastest growth and is Expected to Continue to Do the Same during the Forecast Period

The demand for implantable cardioverter defibrillators is expected to increase during the forecast period. An ICD continuously monitors the heart and automatically delivers therapies to correct fast heart rhythms when necessary. Thus, the high adoption rates can be attributed to the increasing adoption of these devices due to its ability to perform three basic functions, which include defibrillation, cardioversion, and pacing of the heart.

The implantable cardioverter defibrillators segment is further segmented into transvenous ICD and subcutaneous ICD. These devices will transform cardiac procedures through integrated technology to extend and improve lives while decreasing the burden of care and reducing cost.

On the other hand, the pacemaker segment is anticipated to grow at a significant rate over the forecast period due to reimbursement coverage and technological advancements such as exclusive algorithms to accurately detect and reduce the likelihood of atrial fibrillation boost the market share of this segment.

North America Represents the Largest Market and Asia-Pacific is Expected to Register Fastest Growth

Currently, North America dominates the market for CHF treatment devices, and it is expected to continue to dominate in the future. The increasing demand for CHF treatment in the region, the increasing prevalence of target disorders, high expenditure on healthcare, and an increase in awareness are the factors anticipated to drive the market. Moreover, strong clinical pipeline, favorable reimbursement policies for therapeutic products, and higher adoption of these devices are the other factors anticipated to promote the growth in revenue.

The Asia-Pacific region is anticipated to witness lucrative growth over the forecast period. The Asia-Pacific region is estimated to have the largest geriatric population globally, with the highest obesity rates, owing to sedentary lifestyles and unhealthy dietary habits. These factors are expected to increase the prevalence of cardiac diseases in this region. Hence, this factor is expected to witness the growth of the market in Asia-Pacific. In addition, the booming medical tourism industry in this region is expected to fuel the demand for cardiovascular systems in countries, such as China, Japan, Malaysia, Thailand, and India.

Competitive Landscape

The congestive heart failure treatment devices market is moderately fragmented, in terms of competition with many local manufacturers competing with international companies. Companies are more focused on developing high-utility products, which can deliver personalized care. These advancements are improving accuracy, providing additional capabilities to enhance the workflow, and facilitating error reduction.

Some of the market players in this vertical include Medtronic PLC, Boston Scientific Corporation, Biotronik SE & Co. KG, and St. Jude Medical, among others. The operating strategies adopted by these players include new product launches and regional expansions. For instance, in September 2017, Boston Scientific launched resonate devices with HeartLogic heart failure diagnostic.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1.1 Study Assumptions
1.2 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Cardiovascular Diseases (CVD)
4.2.2 Advent of Technological Advanced Products
4.3 Market Restraints
4.3.1 High cost of devices
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Product
5.1.1 Ventricular Assist Devices (VADs) LVAD RVAD BiVAD
5.1.2 Counter Pulsation Devices
5.1.3 Implantable Cardioverter Defibrillators Transvenous ICD Subcutaneous ICD
5.1.4 Pacemakers Implantable External
5.1.5 Cardiac Resynchronization Therapy Cardiac Resynchronization Therapy-Defibrillators (CRT-D) Cardiac Resynchronization Therapy-Pacemakers (CRT-P)
5.2 Geography
5.2.1 North America United States Canada Mexico
5.2.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.2.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.2.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.2.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Berlin Heart
6.1.3 Biotronik SE & Co. KG
6.1.4 Boston Scientific Corporation
6.1.5 Jarvik Heart Inc.
6.1.6 Medtronic Plc
6.1.7 ReliantHeart Inc.
6.1.8 Siemens Healthcare
6.1.9 Teleflex Incorporated




Recommended reports